Company Page

Changed Risks for ENANTA PHARMACEUTICALS INC (ENTA)

Commercial success of our product candidates depends upon significant market acceptance among physicians, patients and healthcare payors of any resulting

, EDP-514

Our relationships with customers and third-party payors in the United States and elsewhere will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties,

If we are required to suspend or discontinue clinical trials due to side effects or other safety risks associated with our product candidates, or if we are

arties to monitor, support, conduct and/or oversee clinical trials of our product candidates that we develop independently and, in some cases, to maintain regulatory files for those product candidates If we are not able to maintain or secure agreements wi

required to conduct studies on the long-term effects associated with the use of any of those product candidates, commercialization any of those product candidates could be delayed or halted

ety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business

or, or commercialize, our product candidates

ture, and our ability to achieve sustained profitability is unproven

th such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us, we may not be able to obtain regulatory approval f

arties

If we fail to comply with environmental, health and saf

We have not developed independently any approved products and we have limited clinical development experience, which makes it difficult to assess our ability to develop and commercialize

Risks Related to Our Intellectual Property Rights

approved drug

We will rely on third p

Risks Related to Our Dependence on Third P

our product candidates

Because we do not anticipate paying cash dividends on our common stock for the foreseeable future, investors in our common stock may never receive a return on their investment

contractual damages, reputational harm and diminished profits and future earnings

To date, our principal sources of revenue have been our collaboration agreements, including our c